A detailed history of Citigroup Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Citigroup Inc holds 60,936 shares of SNDX stock, worth $980,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,936
Previous 36,352 67.63%
Holding current value
$980,460
Previous $746,000 57.24%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.93 - $24.81 $440,791 - $609,929
24,584 Added 67.63%
60,936 $1.17 Million
Q2 2024

Aug 12, 2024

SELL
$18.82 - $23.79 $5.43 Million - $6.87 Million
-288,577 Reduced 88.81%
36,352 $746,000
Q1 2024

May 10, 2024

BUY
$19.71 - $24.57 $3.2 Million - $3.99 Million
162,523 Added 100.07%
324,929 $7.73 Million
Q4 2023

Feb 09, 2024

BUY
$11.39 - $21.67 $480,361 - $913,910
42,174 Added 35.08%
162,406 $3.51 Million
Q3 2023

Nov 09, 2023

BUY
$14.52 - $21.77 $51,110 - $76,630
3,520 Added 3.02%
120,232 $1.75 Million
Q2 2023

Aug 10, 2023

SELL
$19.35 - $22.31 $8.59 Million - $9.9 Million
-443,703 Reduced 79.17%
116,712 $2.44 Million
Q1 2023

May 11, 2023

BUY
$20.66 - $28.98 $6.08 Million - $8.53 Million
294,482 Added 110.74%
560,415 $11.8 Million
Q4 2022

Feb 09, 2023

SELL
$20.64 - $26.24 $5.47 Million - $6.95 Million
-265,053 Reduced 49.92%
265,933 $6.77 Million
Q3 2022

Nov 10, 2022

BUY
$18.51 - $24.79 $1.24 Million - $1.66 Million
67,007 Added 14.44%
530,986 $12.8 Million
Q2 2022

Aug 10, 2022

BUY
$13.64 - $19.48 $6 Million - $8.57 Million
439,793 Added 1818.38%
463,979 $8.93 Million
Q1 2022

May 12, 2022

SELL
$14.84 - $22.15 $1.57 Million - $2.35 Million
-105,901 Reduced 81.41%
24,186 $421,000
Q4 2021

Feb 10, 2022

BUY
$15.23 - $22.47 $1.16 Million - $1.71 Million
76,023 Added 140.62%
130,087 $2.85 Million
Q3 2021

Nov 10, 2021

BUY
$13.87 - $19.8 $749,867 - $1.07 Million
54,064 New
54,064 $1.03 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $910M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.